바이오스펙테이터

바이오스펙테이터 Seunghyun Chon 기자

On September 25, 2017, Jeil Pharmaceutical said that Korea Health Industry Development Institute (KHIDI), a government-affiliated institution, has selected its next-generation innovative type 1 diabetes drug, JP-2266 (low molecular compound), as part of a government program to cultivate blockbuster drugs targeting the global market.

Backed by the government’s R&D grant program, Jeil plans to carry out nonclinical laboratory study in compliance with Good Laboratory Practice regulations for two years followed by a phase I clinical trial at home and abroad.

The company is developing JP-2266 as one of its promising oral diabetes drugs to significantly improve glycemia risk and lessen patients’ inconvenience due to frequent insulin injections because people with type 1 diabetes always need to use insulin.

Company officials said that “Insulin is the only treatment option for type 1 diabetes. Up to date, non-insulin products are still unavailable. Under these circumstances, we will screen the safety and efficacy of JP-2266 as the first non-insulin therapy.”

"The government’s selection of JP-2266 represents JP-2266’s superior efficacy in treating type 1 diabetes in preclinical study,” Kim Jeong-min, director of Jeil R&D Center, commented.

“Through our intensive studies, we will spare no efforts to successfully develop and commercialize JP-2266. It will bring new hope to people with type 1 diabetes who are always exposed to hypoglycemia, let alone the inconvenience of frequent insulin injections.”